Theophylline does not potentiate the effects of a low dose of dexamethasone in horses with recurrent airway obstruction.
Authors: Cesarini C, Hamilton E, Picandet V, Lavoie J P
Journal: Equine veterinary journal
Summary
# Editorial Summary: Theophylline and Dexamethasone in Recurrent Airway Obstruction The potential for theophylline to reduce corticosteroid requirements in equine recurrent airway obstruction (RAO) was investigated by Cesarini and colleagues, who hypothesised that combining the bronchodilator with low-dose dexamethasone might improve treatment efficacy and allow clinicians to minimise steroid exposure in affected horses. Ten horses in acute RAO exacerbation received five different treatment protocols over sequential 7-day periods: intravenous dexamethasone at 0.05 mg/kg once daily, oral dexamethasone at either 0.05 or 0.02 mg/kg daily, oral dexamethasone at 0.02 mg/kg combined with theophylline at 5 mg/kg twice daily, and theophylline monotherapy. Lung function testing at baseline, day 3 and day 7 revealed that only intravenous dexamethasone at the higher dose produced significant improvement by day 3, whilst oral dexamethasone—whether alone or combined with theophylline—and theophylline monotherapy all failed to improve airway function meaningfully. This negative result is clinically important: despite theophylline's corticosteroid-sparing properties in human asthma, it does not potentiate low-dose dexamethasone in horses with RAO, suggesting that practitioners cannot rely on theophylline to reduce steroid doses without compromising therapeutic outcomes. For effective RAO management, higher intravenous dexamethasone doses or alternative combinations warrant consideration rather than attempting to spare corticosteroids through theophylline supplementation.
Read the full abstract on PubMed
Practical Takeaways
- •Theophylline cannot be used as an adjunct to reduce dexamethasone doses in treating equine RAO; practitioners should not rely on combination therapy to lower corticosteroid requirements
- •For RAO exacerbations, intravenous dexamethasone at 0.05 mg/kg remains superior to oral formulations or combination therapies for rapid lung function improvement
- •Oral dexamethasone at low doses is ineffective for RAO treatment in acute exacerbations, so route of administration and dosing strategy require careful consideration
Key Findings
- •Oral dexamethasone at 0.05 mg/kg or 0.02 mg/kg combined with theophylline failed to significantly improve lung function in RAO-affected horses
- •Intravenous dexamethasone at 0.05 mg/kg resulted in significant lung function improvement starting on day 3
- •Theophylline monotherapy at 5 mg/kg twice daily for 7 days did not improve lung function
- •Theophylline does not demonstrate corticosteroid-sparing effects in horses with RAO, unlike its effects in human asthma